New hope for rare gut disease? small study tests ustekinumab
NCT ID NCT07582991
First seen May 14, 2026 · Last updated May 15, 2026 · Updated 1 time
Summary
This study tested the drug ustekinumab in 8 people with a rare and severe form of intestinal Behçet's syndrome that also involves a blood disorder called myelodysplastic syndrome (MDS). The goal was to see if the drug could control gut symptoms and improve disease activity over 24 weeks. Since there are no standard treatments for this combination, the study aimed to find a safe and effective option, but it does not offer a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Rheumatology and Immunology, Peking University People's Hospital
Beijing, 100044, China
Conditions
Explore the condition pages connected to this study.